Latest Breaking News On - Guide therapeutics - Page 4 : comparemela.com
Finch Therapeutics Announces the Appointment of Marc Blaustein as Chief Operating Officer
kulr8.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kulr8.com Daily Mail and Mail on Sunday newspapers.
Finch Therapeutics Announces the Appointment of Marc Blaustein as Chief Operating Officer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
List: 11 Biotechs to Know Leading Gene Editing
businessinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businessinsider.com Daily Mail and Mail on Sunday newspapers.
Apellis taps Beam’s base-editing tech to broaden autoimmune disease scope
Apellis taps Beam’s base-editing tech to broaden autoimmune disease scope
Fresh off its first FDA approval, Apellis Pharmaceuticals is teaming up with Beam Therapeutics, a partnership that will use Beam’s base-editing technology to develop new therapies for complement system disorders. Apellis has committed to pay Beam $75 million to kick off the alliance.
Shares0
Apellis Pharmaceuticals recently won its first FDA approval for a drug that treats a rare blood disorder by hitting a specific target in the complement system, a family of proteins that helps cells of the immune system. The company wants to bring complement system drugs to other diseases in other parts of the body and it is turning to the gene-editing technology of Beam Therapeutics for help.
Dive Brief:
In its latest investment into the field of gene therapy, Biogen has licensed technology that it believes could help create new treatments for central nervous system and neuromuscular disorders.
The deal with Capsigen, a Washington-based biotech, has Biogen paying $15 million at the start and potentially up to $1.3 billion later on, provided certain research, development and sales milestones are hit. Capsigen is also eligible for royalties on future net sales on any resulting products that use its technology.
Capsigen specializes in developing adeno-associated virus vectors, which are used like microscopic shuttles to deliver genetic medicine into human cells. The deal with Biogen tasks Capsigen with creating new capsids the outer coating which protects the genetic payload that are customized to target specific diseases.